| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$40.0M | ROE | −26.70% |
| Net Margin | — | ROIC | −566.60% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $337 | Trading Days | 2395 |
| 52W High | 1.20 |
| 52W Low | 0.01 |
| % Off High | −99.17% |
| YTD | −66.67% | 1Y | −99.02% |
| 3Y | −100.00% | 5Y | −100.00% |
| 10Y | −100.00% | Since incept. (ann.) | −86.60% |
| Ann. Volatility (1Y) | 330.01% | Ann. Volatility (3Y) | 240.29% |
| Sharpe (1Y) | 0.19 | Sharpe (3Y) | −0.52 |
| Max Drawdown (1Y) | −99.02% | Max Drawdown (3Y) | −100.00% |
| Beta (3Y, vs SPY) | 4.07 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $437,590 | — |
| VIVS | VivoSim Labs, INC. | $1.4M | — |
| PHGE | BiomX Inc. | $2.0M | 0.0 |
| CLDI | Calidi Biotherapeutics, Inc. | $2.1M | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $2.9M | — |
| APTOF | Aptose Biosciences Inc. | $4.3M | — |
| LIMN | Liminatus Pharma, Inc. | $4.6M | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $4.9M | — |
| PMCB | PharmaCyte Biotech, Inc. | $6.3M | 0.2 |
| CVM | CEL SCI CORP | $10.0M | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $11.0M |
| — |
| INAB | IN8BIO, INC. | $11.7M | — |
